Что скрывают противозачаточные. Как вернуть контроль над своими гормонами за 30 дней - Джолин Брайтен

Orio, F., et al. “Metabolic and Cardiovascular Consequences of Polycystic Ovary Syndrome”. Minerva Ginecologica 60, no. 1 (2008): 39–51.

Pelusi, B., et al. “Type 2 Diabetes and the Polycystic Ovary Syndrome”. Minerva Ginecologica 56, no. 1 (2004): 41–51.

Pomp, E. R., et al. “Risk of Venous Thrombosis: Obesity and Its Joint Effect with Oral Contraceptive Use and Prothrombotic Mutations”. British Journal of Haematology 139, no. 2 (2007): 289–96.

Raghuramulu, N., et al. “Vitamin D Improves Oral Glucose Tolerance and Insulin Secretion in Human Diabetes”. Journal of Clinical Biochemistry and Nutrition 13, no. 1 (1992): 45–51.

Raitakari, M., et al. “Distribution and Determinants of Serum High-Sensitive C-Reactive Protein in a Population of Young Adults: The Cardiovascular Risk in Young Finns Study”. Journal of Internal Medicine 258, no. 5 (2005): 428–34.

Roach, R. E., et al. “Combined Oral Contraceptives: The Risk of Heart Attack and Stroke in Women Using Birth Control Pills”. Cochrane Database of Systematic Reviews no. 8 (2015): CD011054. Roberfroid, M., et al. “Prebiotic Effects: Metabolic and Health Benefits”. British Journal of Nutrition 104, suppl. 2 (2010): S1–63.

Rocha, S. L., et al. “Heart Attack in a Young Woman – All About Genetics!” Journal of US- China Medical Science 14 (2017): 28–30.

https://www.davidpublisher.com/Public /uploads/Contribute/58b7979d5aba9.pdf.

Rosing, J., et al. “Low-Dose Oral Contraceptives and Acquired Resistance to Activated Protein C: A Randomised Cross-over Study”. Lancet 354, no. 9195 (1999): 2036–40.

Rosing, J., et al. “Oral Contraceptives and Venous Thrombosis: Different Sensitivities to Activated Protein C in Women Using Second- and Third-Generation Oral Contraceptives”. British Journal of Haematology 97, no. 1 (1997): 233–38. Samsioe, G. “Coagulation and Anticoagulation Effects of Contraceptive Steroids”. American Journal of Obstetrics and Gynecology 170, no. 5, pt. 2 (1994): 1523–27.

Samsunnahar, Q. S. A., et al. “Assessment of Coagulation Disorder in Women Taking Oral Contraceptives”. Journal of Bangladesh Society of Physiologist 9, no. 1 (2014): 1–5.

Sasieni, P. “Cervical Cancer Prevention and Hormonal Contraception”. Lancet 370, no. 9599 (2007): 1591–92.

Seeger, J. D., et al. “Risk of Thromboembolism in Women Taking Ethinylestradiol/ Drospirenone and Other Oral Contraceptives”. Obstetrics and Gynecology 110, no. 3 (2007): 587–93.

Shoelson, S. E., et al. “Inflammation and Insulin Resistance”. Journal of Clinical Investigation 116, no. 7 (2006): 1793–1801.

Sidney, S., et al. “Venous Thromboembolic Disease in Users of Low-Estrogen Combined Estrogen-Progestin Oral Contraceptives”. Contraception 70, no. 1 (2004): 3–10.

Singh, B., et al. “Resveratrol Inhibits Estrogen-Induces Breast Carcinogenesis Trough Induction of NRF2-Mediated Protective Pathways”. Carcinogenesis 35, no. 8 (2014): 1872–80.

Skouby, S. O., et al. “Contraception for Women with Diabetes: An Update”. Bailliére’s Clinical Obstetrics and Gynaecology 5, no. 2 (1991): 493–503.

Smith J. S., et al. “Cervical Cancer and Use of Hormonal Contraceptives: A Systematic Review”. Lancet 361, no. 9364 (2003): 1159–67.

Soares, G. M., et al. “Metabolic and Cardiovascular Impact of Oral Contraceptives in Poly cystic Ovary Syndrome”. International Journal of Clinical Practice 63, no. 1 (2009): 160–69.

Sørensen, C. J., et al. “Combined Oral Contraception and Obesity Are Strong Predictors of Low-Grade Inflammation in Healthy Individuals: Results from the Danish Blood Donor Study (DBDS)”. PLoS One 9, no. 2 (2014): e88196.

Tayyebi-Khosroshahi, H., et al. “Effect of Treatment with Omega-3 Fatty Acids on C-Reactive Protein and Tumor Necrosis Factor-Alfa in Hemodialysis Patients”. Saudi Journal of Kidney Diseases and Transplantation 23, no. 3 (2012): 500–6.

Tys-Jacobs, S., et al. “Vitamin D and Calcium Dysregulation in the Polycystic Ovarian Syndrome”. Steroids 64, no. 6 (1999): 430–35.

Vandenbroucke, J. P., et al. “Increased Risk of Venous Thrombosis in Oral-Contraceptive Users Who Are Carriers of Factor V Leiden Mutation”. Lancet 344, no. 8935 (1994): 1453–57.

Van Hylckama, V. A., et al. “The Venous Thrombotic Risk of Oral Contraceptives, Effects of Oestrogen Dose and Progestogen Type: Results of the MEGA Case-Control Study”. British Medical Journal 339 (2009): b2921. Vasilakis, C., et al. “Risk of Idiopathic Venous Thromboembolism in Users of Progestagens Alone”. Lancet 354, no. 9190 (1999): 1610–11.

Vasilakis, C., et al. “The Risk of Venous Thromboembolism in Users of Postcoital Contraceptive Pills”. Contraception 52, no. 2 (1999): 79–83.

Vessey, M., et al. “Oral Contraceptive Use and Cancer. Findings in a Large Cohort Study 1968–2004”. British Journal of Cancer 95, no. 3 (2006): 385–89.

Vinogradova, Y., et al. “Use of Combined Oral Contraceptives and Risk of Venous Tromboembolism: Nested Case-Control Studies Using the QResearch and CPRD Databases”. British Medical Journal 350 (2015): h2135.

Wang, Q., et al. “Effects of Hormonal Contraception on Systemic Metabolism: Cross- Sectional and Longitudinal Evidence”. International Journal of Epidemiology 45, no. 5 (2016): 1445–57.

Westhof, C. L., et al. “Clotting Factor Changes During the First Cycle of Oral Contraceptive Use”. Contraception 93, no. 1 (2016): 70–76.

Williams, M. J., et al. “Association Between C-Reactive Protein, Metabolic Cardiovascular Risk Factors, Obesity, and Oral Contraceptive Use in Young Adults”. International Journal of Obesity and Related Metabolic Disorders 28, no. 8 (2004): 998–1003.

Yan, Y., et al. “Omega-3 Fatty Acids Prevent Inflammation and Metabolic Disorder Trough Inhibition of NLRP3 Infammasome Activation”. Immunity 38, no. 6 (2013): 1154–63.

9. Возьмите под контроль свои перепады настроения, тревожное расстройство и депрессию

Akhondzadeh, S., et al. “Passionfower in the Treatment of Generalized Anxiety: A Pilot Double-Blind Randomized Controlled Trial with Oxazepam”. Journal of Clinical Pharmacy and Therapeutics 26, no. 5 (2001): 363–67.

Almey, A., et al. “Estrogen Receptors in the Central Nervous System and Their Implication for Dopamine-Dependent Cognition in Females”. Hormones and Behavior 74 (2015): 125–38.

Anxiety and Depression Association of America. “Facts & Statistics”. https://adaa.org/about-adaa/press-room/facts-statistics#.

Arbo, B. D., et al. “Effect of Low Doses of Progesterone in the Expression of the GABA(A) Receptor α4 Subunit and Procaspase-3 in the Hypothalamus of Female Rats”. Endocrine 46, no. 3 (2014): 561–67.

Arevalo, M. A., et al. “Selective Oestrogen Receptor Modulators Decrease the Inflammatory Response of Glial Cells”. Journal of Neuroendocrinology 24, no. 1 (2012): 183–90.